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Abstract
Background: Loss of motor neurons in amyotrophic lateral sclerosis (ALS) leads to progressive paralysis and death.
Dysregulation of thousands of RNA molecules with roles in multiple cellular pathways hinders the identification of
ALS-causing alterations over downstream changes secondary to the neurodegenerative process. How many and
which of these pathological gene expression changes require therapeutic normalisation remains a fundamental
question.
Methods: Here, we investigated genome-wide RNA changes in C9ORF72-ALS patient-derived neurons and
Drosophila, as well as upon neuroprotection taking advantage of our gene therapy approach which specifically
inhibits the SRSF1-dependent nuclear export of pathological C9ORF72-repeat transcripts. This is a critical study to
evaluate (i) the overall safety and efficacy of the partial depletion of SRSF1, a member of a protein family involved
itself in gene expression, and (ii) a unique opportunity to identify neuroprotective RNA changes.
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Results: Our study shows that manipulation of 362 transcripts out of 2257 pathological changes, in addition to
inhibiting the nuclear export of repeat transcripts, is sufficient to confer neuroprotection in C9ORF72-ALS patient-
derived neurons. In particular, expression of 90 disease-altered transcripts is fully reverted upon neuroprotection
leading to the characterisation of a human C9ORF72-ALS disease-modifying gene expression signature. These
findings were further investigated in vivo in diseased and neuroprotected Drosophila transcriptomes, highlighting a
list of 21 neuroprotective changes conserved with 16 human orthologues in patient-derived neurons. We also
functionally validated the high neuroprotective potential of one of these disease-modifying transcripts,
demonstrating that inhibition of ALS-upregulated human KCNN1–3 (Drosophila SK) voltage-gated potassium
channel orthologs mitigates degeneration of human motor neurons and Drosophila motor deficits.
Conclusions: Strikingly, the partial depletion of SRSF1 leads to expression changes in only a small proportion of
disease-altered transcripts, indicating that not all RNA alterations need normalization and that the gene therapeutic
approach is safe in the above preclinical models as it does not disrupt globally gene expression. The efficacy of this
intervention is also validated at genome-wide level with transcripts modulated in the vast majority of biological
processes affected in C9ORF72-ALS. Finally, the identification of a characteristic signature with key RNA changes
modified in both the disease state and upon neuroprotection also provides potential new therapeutic targets and
biomarkers.
Keywords: Amyotrophic lateral sclerosis, C9ORF72-repeat expansions, Pre-clinical models, Transcriptome, Genome-
wide mechanisms of neuroprotection, SRSF1-dependent RNA nuclear export, Disease-modifying gene expression
signature, Voltage-gated potassium ion channel
Background
Polymorphic GGGGCC hexanucleotide-repeat expan-
sions in the C9ORF72 gene cause the most common
forms of familial amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia (FTD) [1, 2], a spectrum of
fatal diseases which respectively lead to progressive
death of motor neurons and of neurons in the frontal/
temporal lobes of the brain. While ALS causes progres-
sive paralysis and death usually within 2–5 years from
symptom onset [3, 4], FTD patients present with altered
cognitive features and psychological disinhibition [5]. No
effective disease-modifying therapy is currently available
for these diseases.
Alteration of multiple biological processes in ALS
leads to pathophysiological changes including stress re-
sponses, mitochondrial dysfunction, alterations in axonal
transport, autophagy and protein clearance, cell death,
excitotoxicity, neuroinflammation and dysregulated
astrocyte-motor neuron crosstalk among others [6] in
association with widespread alteration of the RNA me-
tabolism and gene expression [7]. Consistent with this,
the expression levels, alternative splicing and poly-
adenylation site usage of thousands of transcripts are
altered in C9ORF72 repeat-expansion carriers [8, 9].
This raises serious challenges for the identification of
altered transcripts causing neurodegeneration since an
unknown proportion of RNA changes may occur as a
secondary downstream process resulting from disease
progression and dysregulation of RNA-processing fac-
tors. C9ORF72 repeat-expansions contribute to
neuronal injury through three non-mutually exclusive
mechanisms: haploinsufficiency, repeat-RNA seques-
tration of proteins and repeat-associated non-AUG
(RAN) translation of neurotoxic dipeptide-repeat pro-
teins (DPRs), the latter being considered one of the
main drivers of neurodegeneration [10, 11].
We recently showed that repeat-RNA sequestration of
the splicing factor and nuclear export adaptor SRSF1
(serine/arginine-rich splicing factor 1 previously known
as ASF/SF2) triggers the nuclear export of intron-1-
retaining C9ORF72 repeat transcripts which lead to the
cytoplasmic RAN translation of DPRs [12]. Conversely,
depleting SRSF1 confers a selective disease-modifying
approach for neuroprotection in patient-derived neurons
and Drosophila models of disease [12]. Interaction of de-
phosphorylated SRSF1 with NXF1 (nuclear RNA export
factor 1) upon completion of splicing [13, 14] induces
handover of the mRNA through remodeling of NXF1
into a high RNA-binding conformation [15, 16] that
licenses the nuclear export process via transient interac-
tions of NXF1 with the protruding FG-repeats of nucleo-
porins which decorate the channel of the nuclear pore
[17, 18]. The remodeling mechanism of NXF1 provides
in turn a control mechanism to retain un-spliced tran-
scripts within the nucleus [19–21]. C9ORF72 intron-1
repeat-RNA sequestration of SRSF1 is thought to trigger
inappropriate remodeling of NXF1 into the high RNA
affinity mode that promotes the nuclear export of patho-
logical C9ORF72 pre-mRNAs which retain the intron-1
repeat expansions [12, 22].
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The genome-wide functions of SRSF1 have not yet
been investigated in neurons. In proliferative cells, it
contributes to shaping the transcriptome through several
RNA-processing functions involved in: (i) constitutive
and alternative splicing [23–25]; (ii) nuclear export of
mRNAs [13, 15, 26]; (iii) RNA stability/ surveillance [27]
and (iv) release of paused RNA polymerase II from pro-
moters [28]. The functions of SRSF1 have been exten-
sively studied in immortalised and cancer cells, where
overexpression leads to altered splicing functions linked
to transformation and oncogenesis [29, 30]. SRSF1 plays
an essential role in the tissue-specific splicing of the
CaMKIIδ (Ca2+/calmodulin-dependent kinase IIδ) tran-
script that occurs during embryonic development of the
heart, while in contrast, SR-rich proteins are dispensable
to the viability of mature cardiomyocytes [31]. Accord-
ingly, individual depletion (> 90%) of each of the
conserved SRSF1–7 proteins only affected the SRSF1-
dependent nuclear export of 225 transcripts in immor-
talised cells and approximately 100–400 transcripts
for the other SRSF factors, indicating that the NXF1-
dependent nuclear export adaptor function involves
redundancy and/or cooperation [26]. Taken together,
further investigation is required to understand the
genome-wide contribution of SRSF1 function in a
neuronal context.
In this study, we examined the genome-wide mecha-
nisms of neuroprotection by which SRSF1 depletion
confers neuroprotection through investigation of whole-
cell and cytoplasmic transcriptomes from healthy con-
trol and C9ORF72-ALS Drosophila and patient-derived
neurons. Strikingly, the nuclear export inhibition of
C9ORF72 repeat transcripts led to expression changes
for ∼250 human mRNAs involved in multiple disease
pathways out of ∼2250 changes in C9ORF72-ALS
patient-derived neurons, indicating that, while the neu-
rodegenerative process is characterised by a large num-
ber of gene expression changes, a small proportion of
transcript changes is sufficient to suppress the neurode-
generative process. The analysis of SRSF1-depleted
C9ORF72-ALS Drosophila transcriptomes led to a simi-
lar observation with conserved manipulation of cellular
pathways. Moreover, levels of approximately one third of
SRSF1-RNAi induced neuroprotective changes are com-
pletely reversed compared to the disease state, providing
small in vitro and in vivo disease-modifying gene expres-
sion signatures. Finally, based on the integration of hu-
man-Drosophila transcriptomes that identified 16
conserved human neuroprotective transcript changes,
we used pharmacological inhibition and genetic manipu-
lation to show that the expression levels of a conserved
small conductance Ca2+-activated potassium channel,
which is increased in the ALS models, can be manipu-
lated to mitigate the death of human C9ORF72-ALS
motor neurons as well as the neurodegeneration-
associated locomotor deficits in Drosophila.
Methods
Experimental cell and animal models
Patient-derived iNPC lines and differentiation into iNeurons
The human iNeuron cells were derived from iNPC lines
of three healthy controls and three C9ORF72-ALS pa-
tients (Table 1). They have been used in multiple studies
including the manuscript describing the neuroprotective
role of the SRSF1-RNAi depletion [12]. The following
Research Resource Identifiers have been registered for
human iNPC lines 154 (RRID:CVCL_XX76), 155 (RRID:
CVCL_UF81), 3050 (RRID: CVCL_UH66), 78 (RRID:
CVCL_UF8), 183 (RRID:CVCL_UF85) and 201 (RRID:
CVCL_UF86). Control and patient iNeurons were differ-
entiated and cultured exactly as described previously
[12] in 6-well plates (200,000 cells per well) and trans-
duced with 5 MOI LV-Control-RNAi or LV-SRSF1-
RNAi lentivirus for 5 days.
Patient derived iPSC lines and differentiation into motor
neurons
The human motor neurons were derived from human
induced pluripotent stem cells (iPSC) lines (Table 1).
iPSC cells derived from 2 patients carrying the mutation
in C9orf72 (CS28iALS-C9nxx; RRID:CVCL_W558 and
CS29iALS-C9nxx; RRID:CVCL_W559) and 1 iPSC cell
derived from an unaffected control (CS14iCTR-21nxx;
RRID:CVCL_JK54) were obtained from Cedars-Sinai, a
nonprofit academic healthcare organization. The cell line
control MIFF1 (RRID:CVCL_1E69) [32] was kindly pro-
vided by Prof Peter Andrews and Dr. Ivana Barbaric
(Centre for Stem Cell Biology, The University of Shef-
field). iPSCs were maintained in Matrigel-coated plates
(Corning®) according to the manufacturer’s recommen-
dations in complete mTeSR™-Plus™ Medium (StemCell
Technologies). Cultures were replenished with fresh
medium every day. Cells were passaged every 4 to 6 days
as clumps using ReLeSR™ (StemCell Technologies) an
enzyme-free reagent for dissociation according to the
manufacturer’s recommendations. For all the experi-
ments in this study, iPSCs were used between passage
20 and 35, all iPSCs were cultured in 5% O2, 5% CO2 at
37 °C. For Motor Neuron differentiation, neural differen-
tiation of iPSCs was performed using the modified ver-
sion dual SMAD inhibition protocol [33]. Briefly iPS
cells were transferred to Matrigel-coated plates. On the
day after plating (day 1), after the cells have reached
∼100% confluence, the cells were washed once with PBS
and then the medium was replaced with neural medium
(50% of KnockOut™ DMEM/F-12 (ThermoFisher Scien-
tific), 50% of Neurobasal (ThermoFisher Scientific), 0.5×
N2 supplement (ThermoFisher Scientific), 1x Gibco®
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GlutaMAX™ Supplement (ThermoFisher Scientific), 0.5x
B-27 (ThermoFisher Scientific), 50 U/ml penicillin
(Lonza) and 50mg/ml streptomycin(Lonza), supple-
mented with SMAD inhibitors (DMH-1 2 μM;
SB431542–10 μM and CHIR99021 3 μM [[Tocris]). The
medium was changed every day for 6 days. On day 7, the
medium was replaced for neural medium supplemented
with DMH-1 2 μM, SB431542–10 μM and CHIR 1 μM,
All-Trans Retinoic Acid 0.1 μM (RA; StemCell Tech-
nologies) and Purmorphamine 0.5 μM (PMN; Tocris).
The cells were kept in this medium until day 12 when is
possible to see a uniform neuroepithelial sheet. The cells
were then split 1:6 with Accutase (Gibco™) onto matrigel
substrate in the presence of 10 μM of rock inhibitor (Y-
27632 dihydrochloride; Tocris), giving rise to a sheet of
neural progenitor cells (NPC). After 24 h of incubation,
the medium was changed to neural medium supple-
mented with RA 0.5 μM and PMN 0.1 μM, and changed
every day for 6 more days. On day 19 the motor neuron
progenitors were split with accutase onto matrigel-
coated plates and the medium was replaced with neural
medium supplemented with RA 0.5 μM, PMN 0.1 μM,
compound E 0.1 μM (Cpd E; Tocris), BDNF 10 ng/mL
(ThermoFisher Scientific), CNTF 10 ng/mL (Thermo-
Fisher Scientific) and IGF 10 ng/mL (ThermoFisher Sci-
entific). The cells were then fed alternate days with
neuronal medium until day 40.
Drosophila stocks and husbandry
Flies were raised under standard conditions in a humidi-
fied, temperature-controlled incubator with a 12 h: 12 h
light:dark cycle at 25 °C, on food consisting of agar,
cornmeal, molasses, propionic acid and yeast. Transgene
expression was induced using the tissue specific D42-
GAL4 or nSyb-GAL4 driver. The following strains were
obtained from the Bloomington Drosophila Stock Center
(RRIDs indicated): UAS-Luciferase RNAi (BDSC_31603),
D42-GAL4 (BDSC_8816), nSyb-GAL4 (BDSC_51635),
SKMi10378 (BDSC_55475), SKMi09020 (BDSC_51246). The
following strains were obtained from the Vienna Dros-
ophila Resource Center: UAS-SF2-RNAi (VDRC
v27776). UAS-G4C2x3 and UAS-G4C2x36 lines [34]
were a gift from Prof Adrian M. Issacs (Department of
Neurodegenerative Disease, UCL Institute of Neurology,
London). Unless otherwise stated, all experiments were
conducted using male flies.
Pharmacological treatments
In order to evaluate the neuroprotective potential of
apamin (Sigma Aldrich, 178,270), a potent antagonist of
calcium-activated potassium channels KCNN1 and
KCNN3 [35], motor neurons derived from iPSC cells
from unaffected controls and C9ORF72-ALS patients
were exposed to apamin (0.1–10 μM) diluted in neuronal
medium for 72 h. Cells treated with dimethyl sulfoxide
(DMSO; Sigma Aldrich), the vehicle for dilution of apa-
min, were used as a control.
Total, nuclear and cytoplasmic RNAs fractionation from
patient-derived iNeurons
Three wells of a 6-well plate were lysed were lysed in
Reporter lysis buffer (Promega) for 10 min on ice before
centrifugation at 17,000 g, 5 min, 4 °C for subsequent
western blot and total RNA extractions. Six wells of a 6-
well plate were used for nuclear/cytoplasmic fraction-
ations that were performed as described previously [12].
Briefly, cells were lifted from the plates in DEPC PBS,
pelleted by centrifugation at 400 g for 5 min and quickly
washed with hypotonic lysis buffer (10 mM HEPES pH
7.9, 1.5 mM MgCl2, 10 mM KCl, and 0.5 mM DTT).
Cells were then lysed in hypotonic lysis buffer containing
0.16 U μl− 1 Ribosafe RNase inhibitors (Bioline), 2 mM
PMSF and SIGMAFAST Protease Inhibitor Cocktail tab-
lets, EDTA free (Sigma-Aldrich) for 15 min on ice. All
Table 1 List and characteristics of patient-derived neurons used for the genome-wide investigation of SRSF1 depletion by RNA-seq
Patient cell lines Ethnicity Gender Cell type Age at biopsy sample collection (years)
H1 (3050) Caucasian Male Healthy control 68
H2 (155) Caucasian Male Healthy control 40
H3 (154) Caucasian Female Healthy control 55
C9–1 (78) Caucasian Male C9ORF72-ALS 66
C9–2 (183) Caucasian Male C9ORF72-ALS 49
C9–3 (201) Caucasian Female C9ORF72-ALS 66
CS14 Caucasian Female Healthy control 30–35
MIFF1 Caucasian Male Healthy control Unknown
ALS-28 Caucasian Male C9ORF72-ALS 47
ALS-29 Caucasian Male C9ORF72-ALS 47
ALS-29 ISO Caucasian Male Isogenic ALS-29 line lacking the repeat expansion 47
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lysates underwent differential centrifugation (1500 g, 3
min, 4 °C then 3500 g, 8 min, 4 °C and then 17,000 g, 1
min, 4 °C) transferring the supernatants to fresh tubes
after each centrifugation. The pellets from centrifugation
at 1500 g for 3 min were lysed in Reporter lysis buffer
(Promega) containing 0.16 U μl− 1 Ribosafe RNase inhibi-
tors, 2 mM PMSF and Protease Inhibitors for 10 min on
ice and subsequently centrifuged at 17,000 g, 5 min, 4 °C
to obtain the nuclear fractions. RNA was extracted from
total, nuclear and cytoplasmic fractions as detailed
below. Equal volumes of total, nuclear and cytoplasmic
lysates were resolved by SDS–PAGE, electroblotted onto
nitrocellulose membrane and probed using mouse
anti-SSRP1 [1/500 dilution; Abcam #ab26212] and
chicken anti-class III b-tubulin (TUJ1) [1/500; Milli-
pore #AB9354] antibodies. SSRP1 was detected using
HRP-conjugated mouse secondary antibody [1/10000;
Promega #W4021] and TUJ1 was detected using
HRP-conjugated chicken secondary antibody [1/10000;
Promega #G1351].
RNA extraction
250 μl iNeuron total, nuclear or cytoplasmic extracts
were added to 750 μl PureZOL™ (Bio-Rad) to extract the
RNA. Total Drosophila RNA was extracted from Dros-
ophila heads with the specific transgenes driven by D42-
GAL4 which had been ground to a powder under liquid
nitrogen before addition of 250 μl reporter lysis buffer
(Promega) and addition of 750 μl PureZOL™ to the fro-
zen lysates to extract the RNA. Briefly, lysates were
cleared by centrifugation for 10 min at 12,000 g at 4 °C.
One fifth the volume of chloroform was added and tubes
were vigorously shaken for 15 s. After 10 min incubation
at room temperature, tubes were centrifuged 12,000 g,
10 min, 4 °C and supernatants collected. RNA was pre-
cipitated for 30 min at room temperature with an equal
volume of isopropanol and 2 μl glycogen and subse-
quently pelleted at 12,000 g, 20min, 4 °C. Pellets were
washed with 70% DEPC ethanol and re-suspended in
DEPC water. All PureZol™ extracted RNA samples were
treated with DNaseI (Sigma Aldrich) and quantified
using a Nanodrop (NanoDropTechnologies). Fraction-
ated extracts were subjected to RNA extraction using
Direct-zol™ RNA microprep kits (Zymo Research) fol-
lowing the manufacturer’s protocol, including the rec-
ommended in-column DNase I treatment and quantified
using a Nanodrop. RNA quality was then assessed using
a eukaryote total RNA Nano 6000 Kit (Agilent Tech-
nologies) prior to high depth RNA sequencing or micro-
array analysis and qRT-PCR.
Quantitative RT-PCR (qRT-PCR)
Following quantification, 1 μg RNA (iNeurons samples)
or 2 μg RNA (Drosophila samples) was converted to
cDNA using BioScript Reverse Transcriptase (Bioline).
qRT–PCR primers were designed using Origene or
Primer-BLAST and validated using a 1 in 4 serial
template dilution series (standard curve with R2 >
0.97). qRT–PCR reactions were performed in dupli-
cate using the Brilliant III Ultra-Fast SYBR Green
QPCR Master Mix (Agilent Technologies) on a C1000
Touch™ thermos Cycler CFX96™ Real-Time System
(BioRAD) using an initial denaturation step, 45 cycles
of amplification (95 °C for 30 s; 60 °C for 30 s; 72 °C
for 1 min) prior to recording melting curves. qRT–
PCR data was analysed using CFX Manager™ software
(Version 3.1) (BioRAD) and GraphPad Prism (Version
7). The sequences of qPCR primers are provided in
Additional file 1.
Immunofluorescence microscopy
For immunostaining, cells were washed with phosphate-
buffered saline (PBS) and fixed with 4% paraformalde-
hyde (Sigma Aldrich) for 10 min at room temperature.
After fixation samples were washed three times with
PBS and permeabilized with 0.3% Triton X-100 diluted
in PBS for 5 min. The cells were subsequently blocked in
5% Donkey serum (DS; Millipore) for 1 h. After blocking,
cell cultures were incubated with the appropriate
primary antibodies (rabbit anti-Nestin, 1:500 [Biolegend
#841901]; mouse anti-Pax6, 1:200 [Millipore
#MAB5552]; mouse anti-Tuj1, 1:1000 [Biolegend
#801201]; mouse anti-NeuN, 1:1000 [Biolegend #SIG-
39860]; goat anti-Chat, 1:100 [Millipore #AB144P];
mouse anti-SM132 [Biolegend #801701], 1:500; guinea
pig anti-Map2 [Synaptic Systems #188004], 1:1000;
rabbit anti-Caspase 3, 1:200 [Millipore #AB3623]) di-
luted in PBS containing 1% of DS overnight. Cells were
then washed with PBS three times. Fluorescent second-
ary antibodies (Alexa Fluor 488, 555, 594 or 647, diluted
1:400 with DS [ThermoFisher Scientific #A-21202, #A-
21432, A-21450, #A-32744, #A-21206]) were subse-
quently added to the cells and incubated for 1 h. The
samples were washed with PBS three more times and in-
cubated with 1.0 mg/mL 4,6-diamidino-2-phenylindole
(DAPI; Sigma Aldrich) for nuclear staining. As a specifi-
city control, all experiments included cultures where the
primary antibodies were not added. Non-specific stain-
ing was not observed in such negative control condi-
tions. RNA foci were visualized using RNA fluorescence
in situ hybridization (FISH) as described previously [36].
Images were taken with the Opera Phenix™ High Con-
tent Screening System at × 40 magnification using the
Harmony™ Image analysis system. We used 405, 488 and
594 nm and 647 lasers, along with the appropriate
excitation and emission filters. These settings were kept
consistent while taking images from all cultures.
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High-content automated imaging microscopy
To investigate whether apamin protects motor neurons
(MNs) from cells death, MNs were treated with apamin
for 72 h (0.1–10 μM) and then were stained for active
caspase 3, a typical apoptotic marker. MNs were plated
at 2 × 104 cells per well on matrigel-coated 96-well
plates. After treatment, the cells were fixed and stained
for active caspase 3 and MAP2, which was used as a
marker to define the boundary of cells and DAPI for nu-
clear staining. A quantitative imaging analysis of the MN
was conducted through the The Opera Phenix™ High
Content Screening System at × 40 magnification using
the Harmony™ Image analysis system. The following
morphological features were assessed for both treated
and control: percentage caspase-3 positive cells and the
number of fragmented nuclei. At least 25 fields were
randomly selected and scanned per well of a 96-well
plate in triplicate. To identify and remove any false read-
ings generated by the system, three random treated and
untreated wells were selected and counted manually
(blinded to groups).
Drosophila locomotor and lifespan assays
The startle induced negative geotaxis (climbing) assay
was performed using a counter-current apparatus and
D42-GAL4 driver. Briefly, 20–50 flies were placed into
the first chamber, tapped to the bottom, and given 10 s
to climb a 10 cm distance. This procedure was repeated
five times (five chambers), and the number of flies that
remained within each chamber counted. The weighted
performance of several groups of flies for each genotype
was normalized to the maximum possible score and
expressed as Climbing index [37]. For larval crawling as-
says, nSyb-GAL4 was used and wandering third instar
larvae were placed in the centre of a 1% agar plate and
left to acclimatise for 30 s, after which the number of
peristalsis waves that occurred in the following minute
were recorded.
Bioinformatics analysis
Next generation RNA sequencing (RNA-seq)
Total RNA samples with RNA integrity numbers (RIN)
comprised between 9.3 and 10.0 were sent to the Centre
of Genomic Research at the University of Liverpool for
RNA-seq (project LIMS14705). Dual-indexed strand-
specific RNA-seq library were prepared from the submit-
ted total RNA samples using RiboZero rRNA depletion
and the NEBNext Ultra Directional RNA library prepar-
ation kits (New England Biolabs). Paired-end 2x150bp
sequencing was performed on an Illumina HiSeq 4000
platform. RNA-seq reads were quality-checked and
trimmed by the Centre of Genomic Research at the Uni-
versity of Liverpool. Fastaq files were then aligned to the
Human Genome GRCh38 using STAR 2.7 aligner [38]
and the ensembl built on a University of Sheffield Unix
cluster. The RNA-seq data have been deposited in Gene
Expression Omnibus (GEO) under accession number
GSE139900. An average of 104 millions 150 bp paired-
end sequencing reads were obtained (Supplementary
Table 1). Approximately 5–10% of the genome is stably
transcribed in human cell lines [39, 40]. The size of the
human genome is 3 × 109 bp. Therefore according to the
Lander/Waterman equation (Coverage = read length x
number of reads / size of dataset): Transcriptome cover-
age = (2 × 150 bp × 104 × 106 reads) / (3 × 109 bp × 10/
100) = 104 fold.
Comparison of transcription profiles from fibroblasts and
fibroblast-derived cells
Microarray data previously obtained (GEO Accession
number GSE87385) from human fibroblasts, induced as-
trocytes and induced oligodendrocytes were compared
to the transcriptome of induced neurons and post-
mortem laser captured motor neurons (GEO Accession
number GSE29652). After merging all expression data
based on Gene ID (Official Gene Symbol), we obtained
10,688 gene transcripts that were annotated on both the
microarray platform used to define the transcriptome of
fibroblasts, induced astrocytes, oligodendrocytes and
post-mortem motor neurons, as well as the RNA-seq
data relative to induced human neurons. Expression data
of these 10,688 transcripts were normalised across plat-
forms based on expression of housekeeping genes and
groups visualised using the Qlucore visualisation soft-
ware. Principal component analysis (PCA) plots were ob-
tained by performing F-test ANOVA multi-group
comparison analysis applying p-value < 0.01. No fold
change parameter was applied.
RNA-seq analysis: generation of differentially-expressed
transcript lists
Over 80% of trimmed RNA-Seq reads provided by the
Centre for Genomics Research at the University of Liv-
erpool were aligned to the human GRCh38.79 genome
build using STAR2.7 [38]. Supplementary Table S1 pro-
vides numbers and proportion of aligned reads. Quanti-
fication of transcripts abundance was done using the
aligned .bam files with RSEM, a method to accurately
quantify transcripts from RNA-Seq data with or without
a reference genome [41]. Transcripts counts were then
analysed with EdgeR [42] to normalise the data and
quantify differential expression. Data normalisation was
performed using the relative log expression (RLE) imple-
mented in EdgeR. After normalisation, transcripts abun-
dance was filtered for low and no reads. We retained
transcripts for which counts per million (cpm) were
greater or equal than 2 in at least two samples. Tran-
scripts sequenced in each group were compared to one
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another to evaluate transcriptome coverage across our
experimental conditions. For each comparison, we evalu-
ated the biological variation using the maximisation of
the negative binomial dispersion using the empirical
Bayes likelihood function, as implemented in EdgeR.
Differentially-expressed transcript isoforms were com-
puted for fold change FC > 2 and p-value p < 0.05, which
were evaluated using the quasi-likelihood (QL) methods
with empirical-Bayes Test in EdgeR. Differentially-
expressed transcripts were annotated using BioMart [43]
based on their Ensembl transcript Id to recover gene
symbol, gene description and biotype.
RNA-seq analysis: splicing
For the splicing analysis, sequencing reads were aligned
to the GRCh38.79 genome build through STAR two-
pass mode (v2.5.4b) [38]. The gtf file was used as a guide
during the first pass to find the superset of all novel
splice junctions that were then used in the second-pass
to improve the consistency of alignment and quantifica-
tion across these spliced transcripts. The DEXSeq mod-
ule of Bioconductor was used to identify differential
exon usage [44]. We used the python scripts provided by
the package to annotate the genome and to count the
reads overlapping the exons. The significance thresholds
for differential exon usage were set at a Benjamini–
Hochberg false discovery rate of 5%.
Microarray analysis
Drosophila_2 gene expression arrays (Affymetrix) were
used in this study. Total RNA samples were prepared ac-
cording to the manufacturers’ protocol. Briefly, 200 ng of
total RNA was converted into cDNA using an oligo(dT)
which also carries the binding site for T7 RNA polymer-
ase. Following first strand synthesis, residual RNA was
degraded by addition of RNaseH and a double stranded
cDNA molecule was generated using DNA Polymerase I
and DNA ligase. These cDNA molecules were used as a
substrate for the T7 RNA polymerase to produce mul-
tiple copies of antisense RNA using an IVT labelling sys-
tem. The cRNA molecules produced incorporated biotin
labelled ribonucleotides, which acted as a target for the
subsequent detection of hybridization, using fluores-
cently labelled streptavidin. 12.5 μg of cRNA molecules
were heat fragmented and applied to the GeneChips in a
hybridization solution according to the Affymetrix
protocol. Hybridization took place overnight in a rotat-
ing hybridization oven at 60 rpm, 45 °C for 16 h. The
GeneChip arrays were washed using the ThermoFisher
Fluidics Station. After washing and development of the
fluorescent signal, the GeneChip arrays were scanned
using GC30007 scanner. Gene level differential expres-
sion analysis was carried out using Transcriptome Ana-
lysis Console 3.1 (Affymetrix). The. CEL files were
loaded into the software and sorted into the appropriate
groups. Data were normalised using the RMA algorithm
and the resultant grouped. CHP files compared for dif-
ferential analysis. The software used a one way between
subject ANOVA (unpaired) to calculate expression level
differences with default values fold change FC > 2 and p
value p < 0.05. The microarray data have been deposited
in Gene Expression Omnibus (GEO) under accession
number GSE138592.
Statistical analysis of data
For qRT-PCR data, either one-way or two-way ANOVA
(analysis of variance) with Tukey’s correction for mul-
tiple comparisons was used. For D. melanogaster climb-
ing assays, a Kruskal–Wallis nonparametric test with
Dunn’s post-hoc correction for multiple comparisons
was used and data reported as mean ± 95% CI. For D.
melanogaster crawling assays One-way ANOVA para-
metric with Bonferroni’s multiple comparison test was
used and data reported as mean ± SEM. Data were plot-
ted using GraphPad Prism 7. Significance is indicated as
follows; NS: non-significant, P ≥ 0.05; *P < 0.05; **P <
0.01; ***P < 0.001; ****P < 0.0001.
Results
Identifying transcriptomes from healthy and C9ORF72-
ALS human-derived neurons
Depleting SRSF1 mRNA levels by approximately 60%
confers neuroprotection through inhibition of the nu-
clear export and RAN translation of pathological
C9ORF72-repeat transcripts [12]. To investigate the
genome-wide mechanisms by which SRSF1 depletion
confers neuroprotection and evaluate the safety of this
manipulation, we identified whole-cell and cytoplasmic
transcriptomes to investigate RNA changes at expres-
sion, splicing and nuclear export levels. Neurons derived
from induced neural progenitor cells reprogrammed
from the fibroblasts of three different ALS patients har-
bouring C9ORF72-repeat expansion mutations
(C9ORF72-ALS) and three healthy controls (Table 1)
were treated with lentivirus expressing either scrambled
control-RNAi (C-RNAi) or SRSF1-RNAi (ΔSRSF1) prior
to nuclear and cytoplasmic fractionation in the same
conditions and cell lines previously used to show that
partial depletion of SRSF1 confers neuroprotection [12].
Western blot analysis using antibodies directed against
the SSRP1 chromatin remodelling factor confirmed the
absence of nuclear contamination in the cytoplasmic
fractions (Fig. 1a). Similarly to our previous study, treat-
ment of patient-derived neurons with SRSF1-RNAi lenti-
virus led to partial depletion of SRSF1 at mRNA (∼60%)
and protein levels (Fig. 1b-c respectively). We also con-
firmed that the depletion of SRSF1 did not affect the
splicing of C9ORF72 intron-1 (Fig. 1d) and specifically
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inhibited the nuclear export of C9ORF72 transcripts
retaining the pathological repeat-expansions in intron-1,
showing nuclear accumulation and concomitant cyto-
plasmic decrease of these repeat transcripts (Fig. 1e).
We next proceeded to extract total RNA from the
whole-cell and cytoplasmic fractions to analyse genome-
wide RNA expression changes using next generation
RNA sequencing (RNA-seq). Independent triplicates of
rRNA-depleted RNA sequencing libraries were subjected
to high depth RNA sequencing (averaging 104 million
reads per sample, > 100-fold transcriptome coverage;
Table S1) to investigate differential expression and spli-
cing with high confidence in unrelated patient samples,
which present a high level of genetic variability (Material
and Methods). The lists of over 40,000 quantified tran-
script isoforms are presented in Table S2 under 4 tabs
corresponding to each of whole-cell transcriptomes
(WCT) and cytoplasmic transcriptomes (CyT) for either
healthy control (H) or C9ORF72-ALS (C9) patient-
derived neurons treated with C-RNAi or SRSF1-RNAi
lentivirus. Over 13,000 annotated transcripts and 12,000
protein-coding mRNAs were commonly sequenced at
gene level across all conditions reflecting the generation
of datasets with high transcriptome coverage without
notable RNA sequencing bias between transcriptomes
(Fig. 1f-g). Based on cell type-specific transcriptome da-
tabases from human-derived brain cells [45] and mouse
brains [46], we identified the top 20-expressed tran-
scripts in our datasets that are present within (i) the top
1000-specific human-derived neurons and 2034-
enriched mouse brain neurons; (ii) the top 354-specific
human-derived astrocytes and 2616-enriched mouse
brain astrocytes and (iii) the top 260-specific human-
derived oligodendrocytes and 2227-enriched mouse
brain oligodendrocytes (Supplementary Table 3). This
analysis showed that our differentiation protocol suc-
cessfully yields cells with high expression of neuronal
markers (such as NEFL and TUBB3/TUJ1) and low ex-
pression levels of transcripts known to be specifically
enriched in astrocytes (such as GFAP or ALDH1L1) and
oligodendrocytes (such as MOG or MBP) (Fig. 1h).
Moreover, a principal component analysis (PCA) com-
paring induced patient-derived neurons, astrocytes and
oligodendrocytes to their parental fibroblasts clearly
showed specific segregation of the 4 different cell types
away from each other and from the fibroblasts of origin;
with glial cells, i.e. astrocytes and oligodendrocytes clus-
tering closer to each other than to neurons (Fig. 1i).
Moreover, our protocol of differentiation leads to
patient-derived neuron transcriptomes which cluster
close to human post-mortem motor neurons on the
main component of a PCA plot comparing fibroblasts to
motor neurons (Fig. 1j). Overall, high depth RNA-seq
transcriptomes have been generated from cells success-
fully differentiated into patient-derived neurons.
Neuroprotective depletion of SRSF1 preserves the
transcriptomes of human-derived neurons
A multidimensional scale analysis of the 24 identified
transcriptomes (whole-cell and cytoplasmic triplicates
from healthy and C9ORF72-ALS neurons treated with
control- or SRSF1-RNAi lentivirus) shows that the par-
tial depletion of SRSF1 does not overall disrupt the tran-
scriptomes, with maintenance of the genetic variability
between individuals (Fig. 2a). Differentially-expressed
transcript isoforms were selected for fold change FC > 2
and p-value p < 0.05. Despite a marked reduction in the
abundance of sequenced SRSF1 isoforms in the matched
pair of neurons treated with control- or SRSF1-RNAi,
the differential expression of SRSF1 transcripts, which
(See figure on previous page.)
Fig. 1 Generation of whole-cell and cytoplasmic transcriptomes from healthy and C9ORF72-ALS patient-derived neurons. A Three healthy control
and three C9ORF72-ALS (C9-ALS) lines of patient-derived neurons were treated with Ctrl-RNAi (C-RNAi) or SRSF1-RNAi (ΔSRSF1) prior to whole-cell
(T) lysis or nuclear (N) and cytoplasmic (C) fractionation. Western blots were probed for the nuclear chromatin remodelling SSRP1 factor and the
neuronal cytoplasmic marker TUJ1. B Relative expression levels of SRSF1 mRNA in whole-cell patient-derived neurons prepared in A were
quantified using qRT-PCR in biological triplicates following normalization to U1 snRNA levels and to 100% for healthy neurons treated with C-
RNAi (mean ± SEM; one-way ANOVA with Tukey’s correction for multiple comparisons, **: p < 0.01; N (qRT-PCR reactions) = 3). C Western blots
analysis of SRSF1 protein expression in the three healthy and three C9-ALS neuron lines treated with either C-RNAi or SRSF1-RNAi. D Total,
nuclear and cytoplasmic levels of intron1-spliced C9ORF72 transcripts (as measured by the exon1-exon3 junction) were quantified using qRT-PCR
in biological triplicates following normalization to U1 snRNA levels and to 100% for whole-cell healthy neurons treated with C-RNAi (mean ± SEM;
one-way ANOVA with Tukey’s correction for multiple comparisons, NS: non-significant; N (qRT-PCR reactions) = 3). E Total, nuclear and cytoplasmic
levels of unspliced C9ORF72 transcripts retaining intron1 (as measured by the exon1-intron1 junction) were quantified using qRT-PCR in
biological triplicates following normalization to U1 snRNA levels and to 100% for whole-cell healthy neurons treated with C-RNAi (mean ± SEM;
one-way ANOVA with Tukey’s correction for multiple comparisons, NS: non-significant; ***: p < 0.001; ****: p < 0.0001; N (qRT-PCR reactions) = 3). F
Whole cell transcriptome (WCT; left) and cytoplasmic transcriptome (CyT, right) sizes for quantified transcripts at gene level. G Combined WCT
and CyT sizes for quantified transcripts at gene level. H Abundance of neuron (green), astrocyte (red) and oligodendrocyte (blue) markers in the
human derived neurons (combined from all 24 protein-coding transcriptomes shown in Fig. 1F). I Principal component analysis (PCA) plot
representing transcriptomes from patient-derived neurons, astrocytes, oligodendrocytes and fibroblasts of origin. J Principal component analysis
(PCA) plot representing transcriptomes from patient-derived neurons, human post-mortem motor neurons (MN) and fibroblasts of origin
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was experimentally validated (Fig. 1b), provided p-values
overall not statistically significant due to the high vari-
ability of SRSF1 expression between individual subjects
(2 to 5 fold; Table S4).
Lists of differentially expressed transcript isoforms
(total RNA changes) and differentially expressed genes
(DEGs) are provided in Table S5 for annotated and
protein-coding transcripts in WCT and CyT transcrip-
tomes. Changes were investigated in: (i) C9ORF72-ALS
disease (H_C-RNAi versus C9_C-RNAi; tabs 1 & 4);
C9ORF72-ALS neurons treated with SRSF1-RNAi (C9_
C-RNAi versus C9_SRSF1-RNAi; tabs 2 & 5); healthy
control neurons treated with SRSF1-RNAi (H_C-RNAi
versus H_SRSF1-RNAi; tabs 3 & 6). We identified that
the total expression levels of 2257 transcripts (corre-
sponding to 1804 DEGs) are altered in C9ORF72-ALS
(C9-disease group) by comparing the expression of tran-
scripts quantified in healthy and C9-ALS neurons
treated with control RNAi (Fig. 2b-c, Table S5). On the
other hand, the neuroprotective effects of the depletion
of SRSF1 were investigated in either C9ORF72-ALS or
healthy patient-derived neurons by comparing tran-
scripts levels in each cell type treated with control-RNAi
and SRSF1-RNAi (C9-treated and H-treated groups re-
spectively). Thus, comparing transcript levels in
C9ORF72-ALS neurons treated with either control-
RNAi or SRSF1-RNAi lentivirus (C9-treated group)
identified that a total of 362 RNA changes (351 DEGs; <
1% of the transcriptome comprising transcripts from
∼42,500 coding and non-coding genes) is implicated in
the neuroprotection conferred by the partial depletion of
SRSF1 (Fig. 2b-c, Table S5). We also characterised that
the depletion of SRSF1 leads to 684 transcript changes
(642 DEGs; ∼1.5% transcriptome) in healthy neurons
treated (H-treated group) (Fig. 2b-c, Table S5). The very
small proportion of quantified transcript changes in-
duced by the depletion of SRSF1 is in full agreement
with the multidimensional scale analysis that did not
show global alteration of SRSF1-depleted transcriptomes
(Fig. 2a). Consistent with the mRNA splicing and nu-
clear export functions of SRSF1, 72% of manipulated
RNAs in SRSF1-RNAi-treated neurons are protein
coding transcripts (Fig. 2c). However, the SRSF1-RNAi-
induced transcript changes in healthy and C9ORF72-
ALS neurons do not overlap (Fig. 2d) reinforcing the
concept that healthy control and C9-ALS transcriptomes
are very diverse at a global level due to widespread alter-
ation of RNA metabolism in the C9ORF72-ALS disease
state. Interestingly, the expression levels of approxi-
mately a quarter of transcripts altered in disease (80 + 10
or 90 out of 362) are also reciprocally changed upon
neuroprotection (Fig. 2d).
Manipulation of SRSF1 ameliorates multiple dysregulated
pathways in C9ORF72-ALS neurons
A gene ontology (GO) analysis was performed with the
protein-coding lists of WCT DEGs provided in Supple-
mentary Table 5 using DAVID 6.8 [47, 48]. The results
are presented in Table S6 under 3 tabs for the investiga-
tion of biological processes modulated in C9-disease,
C9-treated and H-treated groups. Transcripts altered in
C9-disease encode proteins involved in cell junction/ ad-
hesion, neurogenesis/ axonogenesis, cytoskeleton, cell
signaling, regulation of cell growth and cell death, stress
responses, synaptic signaling, RNA metabolism/ gene ex-
pression, ion transport and cell cycle regulation (Fig. 2e,
C9-disease). Interestingly, despite the fact that the deple-
tion of SRSF1 in healthy control and C9ORF72-ALS
neurons led to different transcript changes (Fig. 2d), the
same pathways are manipulated upon SRSF1 depletion
(Fig. 2e, C9-treated versus H-treated). In agreement with
the proliferative and oncogenic functions of SRSF1 [29,
30], the depletion of SRSF1 in healthy neurons leads to
down-regulation of markers of the G1/S cell cycle transi-
tion and mitosis (Supplementary Figure 1A) as well as of
cell proliferation and cancer markers [49, 50] (Supple-
mentary Figure 1B). Interestingly, reducing the expres-
sion level of SRSF1 also promotes expression of
transcripts involved in neuron differentiation, axonogen-
esis and synaptic transmission (Supplementary Figure
1C), suggesting additional roles of SRSF1 that may pro-
vide neuroprotective benefits beyond inhibiting the nu-
clear export of C9ORF72 repeat transcripts and the
production of DPRs.
(See figure on previous page.)
Fig. 2 Genome-wide effects of the SRSF1 depletion in human healthy and C9ORF72-ALS neurons. A Multidimensional scale analysis of the WCT
and CyT transcriptomes for healthy (blue) and C9-ALS (red) lines of patient-derived neurons treated with C-RNAi or SRSF1-RNAi (Δ). B Volcano
plots representing the genome-wide distribution of differentially-expressed transcripts according to p-values and fold changes for C9-disease
(H_C-RNAi versus C9_C-RNAi), C9-treated (C9_C-RNAi versus C9_SRSF1-RNAi) and H-treated (H_C-RNAi versus H_SRSF1-RNAi) neuron groups. NS:
non-significant; FC: fold changes < 2; P: p-values > 0.05; P & FC: significant p-values (< 0.05) & fold changes (> 2). Red labels indicate the numbers
of significantly down- or up- regulated annotated transcripts. C, D Venn diagrams representing differentially-expressed transcripts at WCT level for
C9-disease, C9-treated and H-treated groups. E Bar charts representing enrichment scores for the 12 top biological processes identified via
functional annotation clustering for the C9-disease group (1470 protein coding DEGs). The enrichment scores corresponding to the 12 altered
biological pathways are also reported for the C9-treated (254 protein-coding DEGs) and H-treated groups (470 protein-coding DEGs). The GO
terms are provided with gene IDs and statistics in Table S6. Numbers at bar extremities indicate the numbers of genes altered in each pathways.
The neuroprotective depletion of SRSF1 mitigates most of the disease-altered pathways
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As shown above and reported in the literature, a broad
range of cellular processes are affected in C9ORF72-
ALS. Remarkably, the neuroprotection conferred by the
depletion of SRSF1 appears to act upon the vast majority
of biological pathways dysregulated in disease with the
exception of synaptic-related signaling which is poorly
manipulated and protein degradation which is up-
regulated upon neuroprotection (Fig. 2e, C9-disease ver-
sus C9-treated). Out of 2257 RNA changes which occur
in 1804 genes in C9ORF72-ALS, manipulating the ex-
pression levels of 362 transcripts only (∼16%, including
261 protein-coding genes) is sufficient to confer neuro-
protection in vitro (Fig. 2c) suggesting that the large ma-
jority of RNA alterations are not directly related to
pathogenesis but are likely to be downstream conse-
quences of the neurodegenerative process. Importantly,
this shows that neuroprotection can be achieved without
mitigating most of the disease-altered transcript changes.
While the precise gene expression changes causing neu-
rodegeneration still remain to be determined, the identi-
fication of 261 neuroprotective mRNAs offers new
promising perspectives to understand disease patho-
physiology and identify novel potential therapeutic tar-
gets for C9ORF72-ALS.
Depletion of SRSF1 confers neuroprotection
independently of genome-wide modulation of splicing
and mRNA nuclear export
The genome wide effects of the neuroprotective deple-
tion of SRSF1 were next investigated at splicing and
mRNA nuclear export levels. For the splicing analysis,
exon reads were extracted from bam files and differences
in exon usage were computed for C9-disease, C9-treated
and H-treated neurons (Methods). This methodology al-
lows the detection of differential splicing in an exon-
centric manner, through the analysis of differential exon
usage between the conditions under study, directly re-
lated to the diversity of genes and, hence, to alternative
splicing. This analysis is independent of the knowledge
of the exact transcript isoform(s) that can often generate
misleading results since one exon can be shared between
several assembled transcripts [51–53]. Table S7 reports
all statistically differentially expressed exons identified at
a false discovery rate of 5% under 6 tabs for either WCT
or CyT: C9-disease (tabs 1 & 4), C9-treated (tabs 2 & 5)
and H-treated (tabs 3 & 6). Table S8 provides a sum-
mary of the changes. Cytoplasmic exon usage changes
are less noisy than the whole-cell samples that contain
processing pre-mRNAs. Altered transcript isoforms that
have been exported into the cytoplasm are also more
likely to have functional consequences at the protein
level. Ninety-nine differentially expressed cytoplasmic
exons were identified in 77 genes in C9-disease, while
no splicing changes were detected in neuroprotected
C9ORF72-ALS neurons and only 6 were found in
SRSF1-depleted healthy control neurons (Fig. 3a). In
particular, no changes were detected in the splicing of
the C9ORF72 transcripts in either C9ORF72-ALS or
healthy control neurons in agreement with qRT-PCR as-
says in Fig. 1d. These data indicate that the partial deple-
tion of SRSF1, although neuroprotective, has no
significant effect on the genome-wide splicing of
transcripts.
We also investigated the potential impact of partial de-
pletion of SRSF1 on the genome-wide nuclear export of
transcripts. Transcript abundance with FC > 3 in the
cytoplasmic transcriptomes were intersected with tran-
scripts not significantly changing in the whole cell tran-
scriptomes (FC < 3) in a similar approach used for
measuring the mRNA nuclear export dependence of
SRSF1–7 proteins in a murine cell line [26]. This ana-
lysis allowed identifying transcripts with altered cyto-
plasmic expression but unchanged steady-state levels e.g.
transcripts with specific nuclear export defects. The nu-
clear export of 177 annotated transcripts, which include
137 mRNAs, is altered in C9ORF72-ALS neurons
treated with SRSF1-RNAi representing 0.4% of the tran-
scriptome while 202 mRNAs have altered nuclear export
in healthy neurons depleted of SRSF1 (Table S9). Ap-
proximately half of the transcripts either showed nuclear
export inhibition or stimulation (Fig. 3b; extended heat
map with transcript IDs in Supplementary Figure 2), in
full agreement with a previous study which identified
nuclear export alterations of 225 transcripts upon deple-
tion of over 90% of SRSF1 in a proliferating cell context
[26]. The absence of significant overlap between the 177
transcripts with altered RNA nuclear export and the 362
transcript changes implicated in the SRSF1-RNAi-
induced neuroprotection (Fig. 3c) suggests that neuro-
protection is conferred independently of the nuclear ex-
port modulation of cellular transcripts, but rather
through inhibition of the nuclear export of pathological
C9ORF72-repeat transcripts which cannot be detected
by RNA-seq due to the pure and repeat GC-rich nature
of the expansions. It was however quantified and con-
firmed by qRT-PCR in Fig. 1e. In a therapeutic view, it
is noteworthy that partial depletion of SRSF1 does not
alter the CaMKIIδ transcript essential to the developing
heart [31] at expression, splicing or nuclear export level.
To experimentally validate the outputs of the bioinfor-
matics analysis, we investigated some of the 4 most
down-regulated and 4 most up-regulated transcripts
identified in the SRSF1-dependent nuclear export list
(Table S9; tab C9-treated ann. transcripts) which repre-
sents a compilation of predicted data from both whole-
cell and cytoplasmic transcriptomes. We used qRT-PCR
to quantify the mRNA expression levels in total, nuclear
and cytoplasmic fractions isolated from healthy and
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C9ORF72-ALS patient-derived neurons treated with ei-
ther control-RNAi or SRSF1-RNAi lentivirus. As pre-
dicted from the bioinformatic investigation, we showed
that the expression levels of RSL1D1, MTCL1, DAPK1,
NUP98 and MSH6, RBM15, USP19, FN1 are indeed re-
spectively decreased and increased in the cytoplasm
while the total levels remain unchanged and the nuclear
expression levels are altered in the opposite direction
(Fig. 3d). Interestingly, fold changes for transcripts with
the highest altered nuclear export were no more than
2.5 fold, indicating that the genome-wide effects of the
SRSF1 depletion on nuclear export is limited (both in
the numbers and FC of affected transcripts) reminiscent
of the study which showed that the family of SRSF1–7
proteins play redundant and/or cooperative roles in the
NXF1-dependent nuclear export adaptor function [26].
Manipulation of SRSF1 modulates multiple dysregulated
pathways in C9ORF72-ALS Drosophila
Partial depletion of SRSF1 suppressed the C9ORF72-re-
peat neurodegeneration-associated locomotor deficits of
G4C2x36 Drosophila [34] through the transgenic expres-
sion of SRSF1-specific RNAi sequences [12]. Here, we
investigated the transcriptomes of Drosophila heads
Fig. 3 Genome-wide investigation of splicing and nuclear export in human neurons depleted of SRSF1. A Bar chart representing the genome-
wide number of identified splicing alterations at exon (purple) or gene (green) level for the C9-ALS-disease, C9-ALS-treated and SRSF1-depleted
healthy neurons. B Genome wide nuclear RNA export analysis of the SRSF1 depletion in C9-ALS patient-derived neurons. The heatmap represents
transcript fold changes for FC > 3 in WCT and FC > 3 in CyT. Red labels shows down-regulated transcripts while green depicts upregulated
transcripts. C Venn diagram comparing the lists of transcripts with altered RNA nuclear export and changed upon neuroprotection in C9-ALS
neurons depleted for SRSF1. D Relative RNA expression levels of RSL1D1, MTCL1, DAPK1, NUP98, MSH6, RBM15, USP19 and FN1 transcripts in total,
nuclear and cytoplasmic fractions were quantified using qRT-PCR in biological triplicates following normalization to U1 snRNA levels and to 100%
for whole-cell healthy neurons treated with C-RNAi (mean ± SEM; two-way ANOVA with Tukey’s correction for multiple comparisons, NS: not
significant; *: p < 0.05, **: p < 0.01, ***: p < 0.001; ****: p < 0.0001; N (qRT-PCR reactions) = 3)
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from the same lines driving G4C2x36 expression by
D42-GAL4: (i) healthy control flies expressing 3 G4C2
repeats and a luciferase-RNAi control (G4C2x3_C-
RNAi); (ii) C9ORF72-ALS model expressing 36 G4C2
repeats and the RNAi control (G4C2x36_C-RNAi); (iii)
C9ORF72-ALS-neuroprotected flies expressing 36 G4C2
repeats and the disrupted SRSF1 allele (G4C2x36_
SRSF1-RNAi).
Lists of differentially expressed transcripts were identi-
fied for FC > 2 and p < 0.05 (Methods). Table S10 reports
changes in: (i) C9-disease (tab 1; G4C2x3_C-RNAi ver-
sus G4C2x36_C-RNAi), (ii) C9-treated (tab 2; G4C2x36_
C-RNAi versus G4C2x36_SRSF1-RNAi), (iii) H vs C9-
treated (tab 3; G4C2x3_C-RNAi versus G4C2x36_
SRSF1-RNAi). Six hundred forty-four DEGs were identi-
fied in C9-disease flies while expression of 1468 and
1559 genes was respectively changed in the C9-treated
and H vs C9-treated groups. Venn diagrams show that
SRSF1-RNAi-induced neuroprotection is achieved with-
out normalizing all of the transcripts that are altered in
disease and that expression levels of 346 transcripts are
altered both in disease and upon neuroprotection
(Fig. 4a). The DAVID ontology analysis is available for
all groups in Table S11 (tabs 1, 2, 3). Transcripts altered
in the C9ORF72-ALS Drosophila heads include bio-
logical processes previously identified in patient-derived
neurons (such as cell signalling, stress responses, and
ion transport) but also changes in defence/ immune re-
sponse, lipid/ carbohydrate metabolisms, neurological
process and learning/ memory (Fig. 4b, C9-disease). On
the other hand, the neuroprotective effects conferred by
the depletion of SRSF1 act again remarkably upon the
vast majority of pathways dysregulated in disease (Fig.
4b, C9-treated). Interestingly, other cellular processes
that were found altered in both C9-disease and C9-
treated patient-derived neurons (such as protein degrad-
ation, gene expression, synaptic-related, cell death regu-
lation, cytoskeleton and cell junction/adhesion) are also
enriched in neuroprotected Drosophila heads (Fig. 4b,
C9-treated). This indicates that the inhibition of the
RAN translation of C9ORF72-repeat transcripts medi-
ated by the depletion of SRSF1 confers neuroprotection
by inducing changes in conserved cellular pathways.
This is amplified in the H vs C9-treated group which
highlights the manipulated pathways that have been
modified in C9-treated flies compared to the healthy ani-
mals and which confer neuroprotection in C9-ALS flies
(Fig. 4b). Highly enriched changes include transcripts in-
volved in cell signaling, synaptic-related processes,
neurogenesis/ axonogenesis and locomotion. Overall, the
modulation of these biological processes appear particu-
larly relevant to a Drosophila model of C9ORF72-ALS
and the mitigation of the neurodegeneration associated
locomotor deficits. Using qRT-PCR assays, we further
experimentally validated that thioredoxin (DHD), the
most downregulated transcript in C9ORF72-ALS Dros-
ophila, and the sodium-dependent nutrient aminoacid
transporter NAAT1 in the ion transport pathway, exhibit
reduced mRNA expression levels in disease while they
are upregulated to normal levels upon SRSF1 depletion
(Fig. 4c) in agreement with the computed DEG lists
(Table S10, C9-disease and C9-treated).
Identifying conserved transcripts reciprocally altered in
disease and upon neuroprotection
The depletion of SRSF1 provides a unique opportunity
to investigate manipulated disease-modifying mecha-
nisms through the identification of gene expression
changes that occur in both C9ORF72-ALS and upon
neuroprotection. The expression levels of only 90 tran-
scripts affected in disease (∼4% out of 2257 RNA
changes) are also altered following SRSF1 depletion
(Fig. 5a). A clustered heat map represents how tran-
scripts are modulated in diseased and neuroprotected
neurons for each individual subject (Supplementary Fig-
ure 3). It is noteworthy that, despite genetic variability
between individuals, the depletion of SRSF1 reverses al-
tered expression levels for almost all disease-associated
transcripts across the cases. This analysis was further
validated by investigating the fold change values calcu-
lated for each of the 90 transcripts which have modified
expression levels in the C9-disease and C9-treated
groups (Fig. 5b, enlarged heatmap in Supplementary Fig-
ure 4, transcript IDs and FC values in Table S12, tab 1).
Remarkably, the altered expression levels of 88 tran-
scripts, which include 68 mRNAs, are completely re-
versed upon SRSF1 depletion. We next sought to
perform the same analysis using the Drosophila tran-
scriptomes and investigated the 346 transcript changes
that are both affected in disease and manipulated upon
SRSF1-RNAi-dependent neuroprotection (Fig. 5c) show-
ing again, as for the human-derived neuron data, that
the transcripts which are downregulated or upregulated
in C9-disease are largely completely reversed in the neu-
roprotected C9-treated flies (Fig. 5d, transcript IDs and
FC values in Table S12, tab 2). The identification of
these disease-modifying gene expression signatures with
transcripts involved in different biological functions that
show reversed expression levels upon neuroprotection in
both in vitro and in vivo models is entirely consistent
with our previous conclusions indicating that the deple-
tion of SRSF1 counteracts multiple disease-altered bio-
logical processes (Figs. 2e and 4b). This reflects the
neuroprotective effects of SRSF1 manipulation at
genome-wide level through inhibition of the nuclear ex-
port of pathological C9ORF72-repeat transcripts and
mitigation of the DPR-associated neurotoxicity which
are known to broadly alter gene expression and multiple
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cellular pathways [54–59]. Changes in RNA expression
levels however do not necessarily mirror protein levels
and further separate studies will be required to confirm
the altered expression of genes identified here at the
functional level.
We next seek to integrate the data obtained in our
patient-derived neuron and Drosophila transcriptomes
by identifying potential RNA expression changes con-
served in disease and upon SRSF1-RNAi-induced neuro-
protection. To this purpose, we used BioMart [43] which
allows identifying orthologous genes and therefore
conserved gene changes in the human and fly disease-
modifying gene expression signatures. Forty
differentially-expressed human genes out of 90 C9-
disease/treated transcript changes have 49 fly homo-
logues while 99 differentially-expressed fly genes out of
346 C9-disease/treated transcript changes have 78 hu-
man homologues (Table S12, tabs 3 and 4). Only 2
orthologous gene changes are commonly predicted to be
up-regulated in the human and fly disease groups while
their expression levels are down-regulated upon neuro-
protection in both the human and fly C9-treated groups:
Fig. 4 Genome-wide investigation of the partial depletion of SRSF1 in C9-disease and C9-treated Drosophila heads. A Venn diagram representing
the numbers of annotated transcripts at gene level identified in the C9-disease (G4C2x3 + Ctrl-RNAi versus G4C2x36 + Ctrl-RNAi), C9-treated
(G4C2x36 + Ctrl-RNAi versus G4C2x36 + SRSF1-RNAi) and H vs C9-treated (G4C2x3 + Ctrl-RNAi versus G4C2x36 + SRSF1-RNAi) groups. B Bar charts
representing enrichment scores for biological processes identified via functional annotation clustering of the whole cell transcriptomes for the
C9-disease (644 DEGs), C9-treated (1468 DEGs) and H vs C9-treated (1559 DEGs) groups. The GO terms are provided with gene IDs and statistics
in Table S11. Numbers at bar extremities indicate the numbers of genes altered in each pathways. Modulated pathways annotated with an
asterisk (*) were also identified in the human patient-derived neuron transcriptomes. The neuroprotective depletion of SRSF1 mitigates most of
the disease-altered pathways. C Relative expression levels of SRSF1, DHD and NAAT1 mRNAs were quantified using qRT-PCR for the indicated
Drosophila lines in biological triplicates following normalization to Tub84b mRNA levels and to 100% for G4C2x3 + C-RNAi Drosophila heads
(mean ± SEM; one-way ANOVA with Tukey’s correction for multiple comparisons; **: p < 0.01, ***: p < 0.001, ****: p < 0.0001; N
(qRT-PCR reactions) = 3)
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Fig. 5 (See legend on next page.)
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human small conductance calcium-activated potassium
channel protein 1 (KCNN1)/ fly small conductance
calcium-activated potassium channel protein (SK) and
the human and fly lysosomal/endosomal transmembrane
proteins CLN3/Cln3. Gene ontology analysis was further
performed on the 40 and 99 differentially-expressed and
conserved genes respectively identified in the in vitro
and in vivo disease-modifying gene expression signatures
(Table S12, tabs 5 and 6). Top enriched categories in
both human and fly include response to abiotic stimu-
lus/ stress response, carbohydrate metabolism and cat-
ion/potassium transport (Fig. 5e) indicating that if only 2
orthologous gene changes are commonly differentially-
expressed, neuroprotection is achieved through manipu-
lation of different genes which are involved in the same
biological processes. Interestingly, the fully conserved
C9-disease/treated changes in CLN3/Cln3 and KCNN1/
SK expression levels are both involved in the ion trans-
port pathway. A heatmap of conserved genes showing at
least one differentially-expressed change in the C9-
disease or the C9-treated groups highlights 19 similar
and 17 opposite direction of orthologous changes (Fig.
5f; Table S12, tab 7). Most orthologous changes are
identified in the C9-disease groups indicating that neu-
roprotection largely involves manipulation of different
genes in C9ORF72-ALS patient-derived neurons and
Drosophila.
To further investigate mechanisms of pathogenesis
and neuroprotection, we identified the conserved gene
changes in the C9-disease and C9-treated transcrip-
tomes. Eight hundred twelve human differentially-
expressed genes out of 1804 DEGs found in C9-disease
(Supplementary Table 5) have 1251 fly homologues and
65 differentially-expressed fly orthologues (Table S13,
tab 1). Two hundred one differentially-expressed fly
genes out of 644 DEGs (Supplementary Table 10) have
143 human homologues and 47 differentially-expressed
human orthologues (Table S13, tab 2). A heatmap of the
conserved changes identified in C9-disease is presented
in Supplementary Figure 5, showing that only a small
proportion of disease-altered gene expression changes
have differentially-expressed orthologues. In addition to
the challenge posed by integrating transcriptomes from
human-derived neurons and Drosophila heads which
contain multiple cell types, this might also be explained
by the fact that only 17.8 and 24.4% of genes have anno-
tated orthologues in the Homo sapiens and Drosophila
melanogaster Ensembl genomes respectively (Supple-
mentary Figure 6A-B). Likewise, 188 human
differentially-expressed genes out of 351 neuroprotective
gene changes have 261 fly homologues and 22
differentially-expressed fly orthologues (Table S13, tab
3) while 510 differentially-expressed fly genes out of
1468 neuroprotective DEGs have 953 human homo-
logues and 17 differentially-expressed human ortholo-
gues (Table S13, tab 4). Only 17 human and 22 fly
orthologous genes are involved in conferring the SRSF1-
RNAi dependent neuroprotection with 13 having similar
changes of direction (Fig. 5g). Conserved manipulation
of these transcripts suggests that manipulation of other
cellular pathways including various metabolic enzymes
and apoptosis likely play important neuroprotective roles
beyond modulation of KCNN1/SK, CLN3/Cln3 and the
ion transport pathway.
Alterations of voltage-gated ion channels have been re-
ported in C9ORF72-ALS [60–63] and previous reports
including patents for pharmacological modulation of SK
channels in ALS indicate a potential role of small con-
ductance Ca2+-activated potassium (SK) channels in
ALS. We therefore experimentally validated our RNA-
seq data using qRT-PCR assays to show that KCNN1/SK
transcripts were indeed up-regulated in the C9-disease
(See figure on previous page.)
Fig. 5 Identifying conserved disease-modifying gene expression signatures and neuroprotective transcripts. A Venn diagram representing
differentially expressed genes (DEGs) identified in the human C9-disease and C9-treated groups. B Identification of a human disease-modifying
gene expression signature. Heatmap representing the computed fold changes (FC) for the common human transcripts modulated in both C9-
disease and C9-treated groups. Red labels show down-regulated transcripts while green depicts upregulated transcripts. C Venn diagram
representing differentially expressed genes (DEGs) identified in the Drosophila C9-disease and C9-treated groups. D Identification of a Drosophila
disease-modifying gene expression signature. Heatmap representing the FC for the common Drosophila transcripts modulated in both C9-disease
and C9-treated groups. Red labels show down-regulated transcripts while green depicts upregulated transcripts. E Gene ontology analysis of
conserved differentially-expressed transcripts identified in the human and Drosophila disease-modifying gene expression signatures carbohydrate
metabolism, ion transport and response to stress as commonly altered in disease and manipulated upon neuroprotection. F Heatmap
representing the computed fold changes for the orthologous genes in the disease-modifying signatures. Red labels show down-regulated
transcripts while green depicts upregulated transcripts. G Heatmap representing the computed fold neuroprotective changes for the orthologous
genes in the C9-treated groups. Red labels show down-regulated transcripts while green depicts upregulated transcripts. H qRT-PCR
quantification of Drosophila SK and human KCNN1 orthologous transcripts. Relative expression levels of SK mRNA was quantified for the indicated
Drosophila lines in biological triplicates following normalization to Tub84b mRNA levels and to 100% for G4C2x3 + C-RNAi Drosophila heads
(mean ± SEM; one-way ANOVA with Tukey’s correction for multiple comparisons; ****: p < 0.0001; N (qRT-PCR reactions) = 3). Relative expression
levels of KCNN1 mRNA was quantified in whole-cell patient-derived neurons in biological triplicates following normalization to U1 snRNA levels
and to 100% for healthy neurons treated with C-RNAi (mean ± SEM; one-way ANOVA with Tukey’s correction for multiple comparisons, ***: p <
0.001, ****: p < 0.0001; N (qRT-PCR reactions) = 3)
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groups and down-regulated to normal expression levels
upon SRSF1-RNAi-induced neuroprotection in the C9-
treated groups (Fig. 5h).
Manipulating SK/KCCN ion channel activity alleviates
C9ORF72-ALS motor neuron death and Drosophila
locomotor deficits
We next wanted to functionally validate that our gene
expression signature is enriched in genes with disease-
modifying potential by testing the effects of manipulat-
ing the conserved Drosophila SK and human SK channel
subunits in C9ORF72-ALS patient-derived neurons and
Drosophila.
Four KCNN1–4 SK channel isoforms are found in the
human genome. Using qRT-PCR quantification, we ob-
served that KCCN1 and KCNN3 transcripts are signifi-
cantly up-regulated in C9ORF72-ALS models while they
are down-regulated upon neuroprotection (Supplemen-
tary Figure 7). On the other hand, KCNN4 is not af-
fected by the depletion of SRSF1, but is drastically
reduced at mRNA level in C9ORF72-ALS patient-
derived neurons. We next sought to functionally investi-
gate the effects of inhibiting the up-regulated KCNN1
(encoding Kca2.1) and KCNN3 (encoding Kca2.3) tran-
scripts in C9ORF72-ALS motor neurons. Motor neurons
were generated from 2 lines each of healthy control
(MIFF1, CS14) and C9ORF72-ALS patients (ALS-28,
ALS-29; Table 1). Motor neurons were differentiated
from neural progenitor cells, which express the charac-
teristic Nestin and Pax6 markers (Supplementary Figure
8), through a 40-day differentiation protocol that leads
to mature motor neurons expressing ChAT (Supplemen-
tary Figure 9). We further validated that C9ORF72-ALS
motor neurons recapitulate RNA foci, a characteristic
pathological hallmark of disease (Supplementary Fig-
ure 10). Interestingly, compared to healthy controls,
C9ORF72-ALS motor neurons displayed significantly
higher levels of caspase-3 positive cells, a marker of
apoptosis (Fig. 6a, top right bar chart), which correlated
with a significant increase in nuclear fragmentation and
apoptosis (Fig. 6a, bottom right bar chart). This offers a
unique opportunity to test the effects of the pharmaco-
logical inhibition of KCCN1/3 channels on C9ORF72-
ALS motor neuron survival. The addition of increasing
concentrations of apamin, an antagonist of KCNN1 and
KCNN3 channels [35], to the motor neuron cultures re-
sulted in a dose-dependent reduction of caspase-3 posi-
tive cells specific to C9ORF72-ALS motor neurons (Fig.
6b). These data show that, consistent with the RNA-seq
investigation, C9ORF72-ALS motor neurons have an en-
hanced expression of KCNN subunits and that inhibiting
the activity of these Ca2+-activated potassium channels,
as in the SRSF1-RNAi intervention, decreases apoptosis
and cell death, promoting in turn neuronal survival.
To further evaluate the neuroprotective potential of
inhibiting the SK channel function in C9-Drosophila,
Ctrl and C9 flies were crossed with two different loss-of-
function SK mutant fly lines (Methods) and locomotor
ability was analysed in hemizygous (male) or heterozy-
gous (female) SK mutants. Strikingly, partial loss-of-
function of SK channel activity significantly restored
both the crawling activity of C9 larvae (Fig. 6c) and the
climbing ability of C9 adult flies (Fig. 6d). Taken to-
gether, beyond highlighting the involvement of SK chan-
nels in C9ORF72-ALS, these data highlight the powerful
approach of our study by targeting SRSF1-mediated
transcriptomic changes to delineate the most C9ORF72-
disease relevant mechanisms and neuroprotective
strategies.
Discussion
Multiple studies have reported thousands of transcrip-
tome changes in C9ORF72-ALS neurons from cell and
animal models as well as from post-mortem human
brains, raising challenges for the identification of altered
expression of transcripts that cause disease. Here, we
combined for the first time in vitro and in vivo tran-
scriptome investigations of C9ORF72-ALS human-
derived neurons and Drosophila with a disease-
modifying strategy of neuroprotection which leads to
specific inhibition of the SRSF1-dependent nuclear ex-
port of pathological C9ORF72 repeat transcripts [12]. In
perfect agreement with published transcriptome studies,
we identified over 2000 transcript changes in human
C9ORF72-ALS affecting cellular pathways involved in
neuronal-related processes, signalling, RNA metabolism,
cell junction/ adhesion, cytoskeleton, cell death regula-
tion and responses to stress [64–66]. Dysregulation in
the expression of genes involved in synaptic-related pro-
cesses, neuron differentiation and membrane hypoexcit-
ability were also reported in C9ORF72-ALS human-
derived neurons [64] while immune response and RNA
processing alterations were also identified in a human
post-mortem ALS brain study which investigated
genome-wide expression changes using samples strati-
fied by disease severity [67].
Strikingly, we discovered that neuroprotection is con-
ferred by manipulating the expression of a small propor-
tion of C9ORF72-ALS-altered transcripts (362
transcripts genome-wide) in addition to inhibiting the
nuclear export of pathological C9ORF72-repeat tran-
scripts and DPR-associated neurotoxicity, known to
cause widespread alteration of gene expression through
disruption of the nucleolus [57], splicing [54, 55] and
nucleocytoplasmic transport of proteins [56, 59] al-
though potentially indirectly [58]. This also implies that,
out of thousands of RNA changes occurring in
C9ORF72-ALS, the vast majority of diseased gene
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expression changes occur secondary to the neurodegen-
erative process and a complete reversal is not required
to achieve a neuroprotective effect. In both C9ORF72-
ALS human-derived neurons and G4C2x36 Drosophila,
the expression of approximately one third of the SRSF1-
RNAi-manipulated transcripts altered in disease is com-
pletely reversed upon neuroprotective depletion of
SRSF1, revealing in turn in vitro and in vivo C9ORF72-
ALS disease-modifying small gene expression signatures.
Identifying these out of thousands of RNA changes oc-
curring in C9ORF72-ALS provides a novel exciting basis
to evaluate disease-modifying treatments, discover po-
tential new biomarkers and importantly pinpoint a small
number of new targets with therapeutic potential.
To demonstrate the power identification of our
disease-modifying transcript approach and emphasizing
that our data integration leads to the identification of
neuroprotective changes, we further showed that de-
creasing the activity of conserved SK potassium chan-
nels, which are upregulated in disease, mitigates the
death of human-derived motor neurons as well as loco-
motor deficits in Drosophila. Our genome-wide
Fig. 6 Pharmacological and genetic manipulation of KCCN channels promotes C9-ALS MNs survival and Drosophila locomotor function. A High
content images of caspase 3 and MAP2 positive motor neurons from two control (MIFF1 & CS14) and two C9ORF&2-ALS (ALS-28 & ALS-29) lines.
Scale bars: 50 μm. Bar charts represent the percentage of caspase 3 positive cells (top right) and of apoptotic cells measured by nuclear
fragmentation (bottom right) in healthy and C9-ALS patient-derived motor neurons (mean ± SEM; one-way ANOVA Tukey’s multiple comparison
test, ****: p < 0.0001; N (replicate experiments) = 3). B High-content microscopy automated imaging quantification of caspase-3 positive cells (%)
treated with DMSO or increasing concentrations of the KCNN1/3 inhibitor apamin (APA) in healthy, C9-ALS and isogenic CRISPR-Cas9 mediated
deletion of the repeat expansion (ISO) patient-derived motor neurons (mean ± SEM; two-way ANOVA Tukey’s multiple comparison test, ****: p <
0.0001; N (replicate experiments) = 3). C Larval crawling ability of male and female control (G4C3x3) or C9-ALS (G4C2x36) Drosophila crossed or
not with two different SK mutant lines driven by nSyb-GAL4 (mean ± SEM; one-way ANOVA; ns: non-significant, *: p < 0.05, **: p < 0.01, ****: p <
0.0001; N (Drosophila larvae) > 5). D Climbing ability of male and female control (G4C3x3) or C9-ALS (G4C2x36) Drosophila crossed or not with
two different SK mutant lines driven by D42-GAL4 (mean ± 95% CI; Kruskal-Wallis with Dunn’s correction; ns: non-significant, *: p < 0.05, **: p <
0.01, ****: p < 0.0001; N (Drosophila flies) > 25)
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investigation indicated that the nuclear export of
KCNN1–3 transcripts is not dependent on SRSF1 (Table
S9) however the disease-altered overexpression of
KCNN1–3/SK mRNAs is down-regulated to physio-
logical levels under SRSF1-RNAi-induced neuroprotec-
tion in both C9ORF72-ALS patient-derived neurons and
Drosophila (Figs. 5f-h, S7). This interestingly suggests
that the SRSF1-dependent inhibition of the nuclear ex-
port of C9ORF72-repeat transcripts and RAN translation
of DPRs, which cause broad dysregulation of the RNA
metabolism, restores the normal expression of KCNN1–
3/SK and other disease-altered transcripts which exhibit
reversed expression upon neuroprotection.
Taken together, this investigation provides further val-
idation that the partial depletion of SRSF1 is a promising
gene therapy approach for neuroprotection, showing
minimal effects of SRSF1 depletion on the splicing and
nuclear export of cellular transcripts in either healthy or
C9ORF72-ALS neurons at a global genome-wide level.
Our results are in perfect agreement with an independ-
ent study showing redundant/ cooperative roles of
SRSF1–7 in the NXF1-dependent nuclear mRNA export
adaptor function [26]. Consistent with this, the bulk nu-
clear export of human mRNAs is driven by the
Transcription-Export (TREX) complex [68–70], inde-
pendently of SRSF1 which is not associated to TREX
[71], as simultaneous depletion of two TREX subunits
(including the general mRNA nuclear export adaptor
Alyref) leads to a drastic reduction in the genome-wide
recruitment of NXF1 onto polyadenylated mRNAs [72].
Finally, our data demonstrate genome-wide efficacy of
the neuroprotective depletion of SRSF1 with a remark-
able mitigation of multiple unrelated cellular pathways
altered in C9ORF72-ALS. In conclusion, the mecha-
nisms of neuroprotection conferred by the partial deple-
tion of SRSF1 involve both changes in the expression of
a small number of neuroprotective transcripts encoding
proteins involved in various functions (ion transport,
RNA metabolism, synaptic transmission, etc.) as well as
the inhibition of the nuclear export of C9ORF72 repeat
transcripts and the subsequent translation of dipeptide
repeat proteins that also trigger widespread gene expres-
sion alterations and neurodegeneration [54–59, 73].
Additional neuroprotective benefits provided by the de-
pletion of SRSF1, which leads to the stimulation of tran-
scripts encoding proteins involved in neuron
differentiation, axonogenesis and synaptic transmission
(Figure S1C), may explain why the partial suppression of
one fly ALYREF gene, which was initially reported as a
suppressor of C9ORF72-repeat mediated neurotoxicity
in a Drosophila loss-of-function screen [74] and also
identified as a binding partner of C9ORF72-repeat RNAs
[36, 75], provide poor mitigating effects on the loco-
motor deficits of C9ORF72-ALS Drosophila [12].
Interestingly, altered cytoplasmic distribution of SRSF1
has been reported within the infarcted area of stroke vic-
tims when compared to the contralateral area, implicat-
ing a role for the cytoplasmic localisation of SRSF1 in
tissue repair after ischaemia [76]. Several cytoplasmic re-
lated functions have also been reported for SRSF1, in-
cluding nonsense-mediated decay (NMD) through the
RS domain [27], mRNA degradation of specific targets
[77], autoregulation of its mRNA through binding to its
3’UTR to prevent translation initiation [78], targeting of
mRNAs to stress granules following stress [79, 80] and
translation regulation [81, 82]. It remains unknown
whether this potential role in neuronal tissue repair is
due to an impairment in the nuclear functions of SRSF1
or an enhancement of its cytoplasmic roles. Interestingly,
our study which pinpoints neuroprotective benefits fol-
lowing partial depletion of SRSF1 would suggest that the
nuclear reduction of SRSF1 may be the factor contribut-
ing to neuronal tissue repair after ischaemia through
stimulation of the expression of transcripts involved in
neuron differentiation, axonogenesis and synaptic trans-
mission. Further investigation is now required to validate
the potential safety and efficacy of the partial depletion
of SRSF1 in the brain and spinal cords of pre-clinical
mammalian models of C9ORF72-ALS/FTD.
Conclusions
Thousands of gene expression changes, involving altered
expression and splicing of transcripts, are typically iden-
tified in neurodegenerative diseases such as ALS. Here,
we show for the first time that modulating 16% of hu-
man disease-altered transcripts only (362 out of 2257
total pathological changes) is sufficient to confer the
SRSF1-RNAi dependent neuroprotection previously
identified as a promising novel gene therapy approach in
C9ORF72-ALS patient-derived neurons and Drosophila
[12]. Importantly, we found that the partial depletion of
SRSF1 does not significantly alter transcriptomes (< 1%)
preserving the intrinsic variability of gene expression
across individuals. It further leads to the neuroprotective
manipulation of key transcripts involved in the vast ma-
jority of C9ORF72-ALS-altered biological processes
without significantly affecting genome-wide splicing
(none) or mRNA nuclear export (0.4% transcriptome
with modulations < 2.5 fold). Overall, our genome-wide
investigation provide a solid rationale for the efficacy
and safety of the partial depletion of SRSF1 in vitro and
in vivo in preclinical patient-derived neurons and Dros-
ophila models of C9ORF72-ALS. Integrating data be-
tween RNA-seq and microarrays as well as between
diseased/neuroprotected human-derived neurons and
Drosophila heads allowed identification of a disease-
modifying signature with few but conserved neuropro-
tective targets with high therapeutic potential.
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